Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><i>First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment</i><p align="center"><i>New translational data...